Abstract Recent FDA approval of new GLP-1 agonists drugs focused on weight loss has been met with a surge in use of drugs such as Wegovy and Zebound
It is a single-dose, controlled research exposure in a small sample, which cannot predict the effects of repeated, unsupervised cannabis use.What risks does this study not address?It does not address mood destabilization, mania or hypomania risk, psychosis risk, sleep, medication interactions, or cannabis use disorder, all established concerns in bipolar disorder.Should patients change their cannabis use based on this study?No
Except for the ER, intracellular GSH is mainly found in its reduced form
99% Purity : Manufactured with 99% purity , GLP-1 R (50mg) ensures the highest quality for preclinical studies , clinical trials , and metabolic health research , offering consistent and reliable results